Table 1. Clinical characteristics of patients.
| Characteristics | Value (n=31) |
|---|---|
| Age (years) | 62 [43–75] |
| ≥60 | 19 (61.3) |
| <60 | 12 (38.7) |
| Gender | |
| Male | 27 (87.1) |
| Female | 4 (12.9) |
| KPS score | |
| ≥80 | 30 (96.8) |
| <80 | 1 (3.2) |
| Smoking history | |
| Yes | 20 (64.5) |
| No | 11 (35.5) |
| Clinical stages | |
| LD | 15 (48.4) |
| ED | 16 (51.6) |
| Pattern of relapse after the first-line chemotherapy | |
| Platinum-sensitive disease (progression ≥90 days) | 20 (64.5) |
| Platinum-refractory disease (progression <90 days) | 11 (35.5) |
| Whether patients received radiotherapy before NGS sequencing? | |
| Yes | 28 (90.3) |
| No | 3 (9.7) |
| Prior lines of therapy before NGS sequencing | 2 [1–3] |
| 1 | 16 (51.6) |
| 2 | 13 (41.9) |
| 3 | 2 (6.5) |
| Time from diagnosis to DNA sequencing (months) | 10.9 [2.1–47.6] |
| TMB | 6 [1–66] |
| Low, TMB <20 | 26 (83.9) |
| Medium, 20≤ TMB <40 | 3 (9.7) |
| High, 40≤ TMB <60 | 1 (3.2) |
| Very high, TMB ≥60 | 1 (3.2) |
| MSI/MSS | 12 [4.1–32.0] |
| Stable (MSS), MSI <20 | 27 (87.1) |
| Moderate instable (MSI), 20≤ MSI <40 | 4 (12.9) |
| High instable (MSI-H), 40≤ MSI <60 | 0 (0.0) |
| Very high instable (MSI-VH), MSI ≥60 | 0 (0.0) |
| Genomic alterations per sample | 5 [1–11] |
Values are presented as median [range] or n (%). KPS, Karnofsky performance status; LD, limited disease; ED, extensive disease; NGS, next-generation sequencing; TMB, tumor mutation burden; MSI, microsatellite instability; MSS, microsatellite stability; MSI-H, MSI-high; MSI-VH, MSI-very high.